| Name | Title | Contact Details |
|---|---|---|
Michael Blaha |
Senior Director of Cloud Operations | Profile |
Ellie Diagnostics was founded to offer vets a simpler way to diagnose and treat animals with confidence, while helping animals live longer, healthier lives.
Southwestern Health Resources, which blends the strengths of University of Texas Southwestern Medical Center and Texas Health Resources, includes a network of 29 hospital locations and more than 5,000 physicians, committed to being the national leader in population health. With more than 500 points of access to care, this provides for higher value and allows patients to access services across a full continuum of medical needs. The network serves people across 17 counties in North Texas. In total, Southwestern Health coordinates care for more than 650,000 patients, aligned with commercial health care plans and Medicare programs. SWHR operates the nation`s highest rated Next Generation Accountable Care Organization for savings.
Ability Services Network Inc is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Meta Pharmaceutical Services is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.